title,datetime,impact_score,sentiment,summary,article
"Dillard’s, Inc. Announces $0.25 Cash Dividend",2024-05-18T17:28:00.000Z,Low,Neutral,"Dillard’s announced a $0.25 cash dividend per share on both its Class A and Class B Common Stock. The dividend is set for distribution on August 5, 2024, to shareholders of record by June 28, 2024.",
"Transition Metals Further Strengthens Board, Appointing Ashley Kirwan as Director",2024-05-18T15:06:00.000Z,Neutral,Neutral,"Transition Metals Corp has appointed Ashley Kirwan to its Board of Directors, effective April 29, 2024. This addition increases the board to six directors, five of whom are independent. Kirwan, a professional geologist with over 15 years of experience, co-founded Orix Geoscience and holds several directorships. She has received multiple industry awards, including the Top 40 Under 40 by the Sudbury Chamber of Commerce, YWCA Women of Distinction Award, and The Eira Thomas Young Mining Professional award. Additionally, Transition Metals issued 2,090,000 stock options, 350,000 RSUs, and 1,700,000 DSUs to its directors, officers, and employees. The stock options can be converted at $0.06 per share for five years, RSUs vest in three years, and DSUs vest upon the holder's loss of office.",
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis,2024-05-18T12:30:00.000Z,Neutral,Neutral,"Gilead Sciences (GILD) has announced interim results from the ASSURE study, which show that seladelpar, an investigational PPAR delta agonist, significantly improves liver disease markers and reduces itching in primary biliary cholangitis (PBC) patients. The study enrolled 174 patients, with 70% of those treated for 12 months meeting the composite endpoint, and 37% achieving ALP normalization. Seladelpar also reduced other liver injury markers. No serious adverse events were reported. This data aligns with the Phase 3 RESPONSE study, highlighting seladelpar's potential as a new therapy for PBC. The FDA has accepted a New Drug Application for seladelpar, with a decision expected in August 2024.",
Faraday Future Announces Fourth Quarter and Full Year 2023 Earnings Webcast Timing,2024-05-18T04:05:00.000Z,Neutral,Neutral,"Faraday Future (NASDAQ: FFIE), a California-based intelligent electric mobility company, will announce its fourth quarter and full year 2023 earnings on May 28, 2024. The conference call for the results is scheduled at 5:00 p.m. PT (8:00 p.m. ET). Investors can access the webcast via the Investor Relations section on the company’s website, with a replay available afterward.",
Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting,2024-05-18T11:00:00.000Z,Neutral,Neutral,"Mirum Pharmaceuticals presented data on their oral solution, LIVMARLI (maralixibat), at the 56th ESPGHAN Annual Meeting in Milan. Seven abstracts highlighted LIVMARLI's efficacy in treating Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC). Key findings from the Phase 3 MARCH-ON PFIC study showed significant and sustained improvements in pruritus severity, serum bile acid levels, total bilirubin, and growth over two years. One-third of patients on LIVMARLI discontinued at least one antipruritic medication. These results underscore LIVMARLI's potential in improving liver health and reducing medication dependency in children with PFIC and ALGS.",
MODULAR ATP Study of the mCRM™ System Meets Primary Safety and Efficacy Endpoints,2024-05-18T15:03:00.000Z,Moderate,Neutral,"Boston Scientific announced positive six-month results from the MODULAR ATP study of the mCRM System, which integrates the EMBLEM S-ICD and EMPOWER LP. The study met all safety and efficacy endpoints, showing a 97.5% major complication-free rate and a 98.8% communication success rate between devices. The ATP success rate was 61.3%, with no patients requesting therapy deactivation. The EMPOWER LP demonstrated stable device fixation. Findings were presented at Heart Rhythm 2024 and published in The New England Journal of Medicine. The APPRAISE ATP trial also supported the modular therapy approach, showing a small reduction in first all-cause shocks over five years in a large patient group. FDA approval is anticipated in 2025.",
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 Digestive Disease Week® (DDW),2024-05-18T11:00:00.000Z,Moderate,Negative,"Mallinckrodt presented data on TERLIVAZ® (terlipressin) for treating hepatorenal syndrome (HRS) at the 2024 Digestive Disease Week in Washington, DC. The presentations included a post-hoc analysis from the Phase III CONFIRM trial and a pooled analysis of three Phase III studies. The results indicate that TERLIVAZ is effective in improving kidney function in patients with HRS-AKI, even with dose interruptions, and is particularly beneficial for patients with baseline serum creatinine (SCr) levels below 5 mg/dL. TERLIVAZ is the first FDA-approved treatment for HRS with rapid kidney function decline, impacting over 42,000 Americans annually. The safety profile includes risks of serious respiratory failure and ischemic events, and the treatment is not recommended for certain high-risk patients.",
